COVID Rapid Testing Market By Sales Channel (Direct, Indirect); By End-Users (Hospitals, Clinics, Laboratories, Pathological Centres, Research Institutes, Others); By Specimen Type (Nasal Swab, Nasopharyngeal (NP) Swab, Oropharyngeal (OP) Swab, Blood Plasma/Serum/Whole Blood, Others); By Testing Type(Antigen Testing, Antibody Testing); By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2020 – 2028
Industry Trends
Coronavirus infection has spread globally since its detection in Hubei province of China in December 2019. As number of individuals that have shown symptoms of COVID-19 are increasing, a series of computed tomography (CT) tests were performed on these patients. These tests have shown varied results as compared to images of an healthy individuals lungs. Later bronchoalveolar lavage (BAL) fluid of these patients were analyzed which proved that the pathogen has similar genetic sequence to the betaCoronavirus B lineage, and genome similar to that of severe acute respiratory syndrome virus (SARS-CoV). This virus has spread rapidly across continents causing a global pandemic. A multitude of tests including CT imaging, whole genome sequencing and electron microscopy were initially performed to identify COVID-19 patients. However, these techniques were time consuming and had less throughput to cope with the higher in-flow of patients. The number of reported cases of COVID-19 has crossed 31 million mark worldwide with more than 270,000 new cases being reported each day. The rise in number of COVID-19 patients has created a high demand for rapid, point-of-care diagnostics. Rapid diagnostic tests for COVID-19 detect the presence of viral proteins (antigens) related to this virus in a sample from the respiratory tract of a person. They also help in the detection of antibodies in blood or serum, of human which are generated in response to the infection. These tests have the capability of producing results in less than 30 minutes. Thus, this higher demand for faster diagnosis of COVID-19 patients is fuelling the adoption of COVID rapid testing market.
The exponential spread of COVID-19 virus has resulted in shortages of laboratory-based molecular testing equipment and reagents. This has encouraged diagnostic test manufacturers to develop rapid and easy-to-use testing kits which facilitate testing outside of laboratory settings. Companies are utilizing advanced technologies either in their products to provide rapid testing capabilities. For instance, Mylab Discovery Solutions Pvt. Ltd. launched a machine in July 2020 to automate the molecular diagnostic tests, including RT-PCR tests for COVID-19. Also, Oak Ridge National Lab has instructed Coca-Cola Consolidated, Inc., to utilize its advanced injection moulding manufacturing machine to assist in the development of COVID test kits. Government bodies are also supporting the use of advanced technologies to develop rapid testing solutions for COVID-19. In July 2020, for instance, the U.S National Institutes of Health (NIH) announced an investment of US$ 248.7 million for advancement of technologies that aids in rapid COVID-19 testing. Thus, the incorporation of advanced technologies in products to overcome the shortages of in laboratory testing, coupled with the increasing support by government bodies for the development of rapid testing kits is fuelling the growth of the global COVID rapid testing market.
Concerns regarding costs, compliance and accuracy of rapid testing kits is hindering the growth of the global COVID rapid testing market. World Health Organization recommended that the rapid point-of-care testing should be used only for research purposes, and not in other settings due to the lack of empirical studies that supports its efficiency. Also, multiple instances have been reported where the offerings from many market players have failed to produce accurate results. For instance, the U.S. Food and Drug Administration agency issued an alert in May 2020 regarding the usage of Abbott’s ID NOW rapid COVID test due to its failure in accurately testing the White House staff. Similarly, in May 2020, Dubai Health Authority (DHA) banned the use of rapid viral tests for COVID-19 owing to its inaccuracies in test results. The irregularity in test results, coupled with the lack of documented studies related to the efficiency of rapid test kits is restraining the growth of COVID rapid testing market across the globe.
Sales Channel Outlook:
As government bodies across various nations have imposed partial or full lockdowns to contain the spread of COVID-19 pandemic, medical professionals are shifting towards online channels for procuring essentials. This trend has resulted in shift of COVID rapid test kit manufacturers towards adopting online indirect channel of distribution. Online integrators such as Allumer Medical Pvt. Ltd., BiolinxLabsystems Private Limited, amongst others, are selling rapid test kits, thus contributing towards the share of indirect sales channel in the global COVID rapid testing market.
Testing Type Outlook:
The type of tests depends on the user demands, and the circumstances. In case an individual wants to know the current status of infection, antigen tests are usually performed. However, if immunity needs to be tested against this virus then antibody tests are performed. Antigen tests dominate the global COVID rapid testing market owing to high demand of diagnosis from the growing number of infected people. In the rapid antigen tests for COVID, samples from either Nasopharyngeal (NP) or Oropharyngeal (OP) swabs of patients are taken. If the target antigen is present in sufficient concentrations in the sample, it will bind to specific antibodies fixed to a paper strip enclosed in a plastic casing, and generate a visually detectable signal. Market players such as Fujirebio, Abbott, RapiGENInc., etc., are providing antigen COVID rapid test kits. However, the medical care providers are adopting plasma treatment therapies to treat active COVID-19 patients. Therefore, antibody testing is gaining momentum to test presence of antibodies in cured patients or either the immune patients. These tests also assists researchers in development of COVID-19 vaccines. The demand for antibody testing is attracting new market players into this sphere. For instance, Hoffmann-La Roche Ltd. launched a new ARS-CoV-2 antibody test in September 2020 to support the evaluation of vaccines and plasma therapy. These factors are anticipated to propel the share of antibody tests in the global COVID rapid testing market.
Regional Outlook:
North America region registered the highest share in global COVID rapid testing market. Countries such as the U.S and Mexico in North America region witnessed a high number of COVID-19 cases. Furthermore, COVID-19 graph is on the rise, and the growth in infected individuals is causing concerns amongst public health officials. Statistics from Center for Disease Control and Prevention agency in the U.S. show that the total number of COVID-19 cases as of September 22, 2020 has crossed 6.825 million. Isolation of affected individuals has been identified as the fastest and the most efficient procedure to curb the spread of the virus. Thus, the high number of COVID cases, especially in the U.S., and the rising demand for faster diagnostics in the region is pushing the growth of the global COVID rapid testing market.
In terms of revenue, global COVID rapid testing market is expected to reach US$ 5650.0 Mn in 2020 and is anticipated to grow at a CAGR of 15.23% over the forecast period. The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global COVID Rapid Testing Market Revenue & Forecast, (US$ Million), 2020 - 2028
Competitive Landscape
The report provides both, qualitative and quantitative research of COVID rapid testing market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the COVID rapid testing market are Abbot, Beijing Tigsun Diagnostics Co.Ltd., BGI, Biolidics Limited, BioMaxima SA, BIOMEDOMICS INC., bioMérieux SA, Bio-Rad Laboratories, Inc., Cellex, Cepheid, Co-Diagnostics, Inc., CTK Biotech, Inc., F. Hoffmann-La Roche Ltd, GenMark Diagnostics, Inc., GeteinBiotech,Inc., LaboratoryCorporation of America Holdings. (Pixel), Megna Health, Meridian Life Science, Inc., Mylab Discovery Solutions Pvt. Ltd., QIAGEN, Quidel Corporation, Randox Laboratories Ltd., RayBiotech, Inc., SD Biosensor, INC., Seegene Inc., Thermo Fisher Scientific Inc. and Ubio Biotechnology Systems Pvt Ltd amongst others.
Global COVID Rapid Testing Market:
By Sales Channel
- Direct
- Indirect
By End-Users
- Hospitals
- Clinics
- Laboratories
- Pathological Centres
- Research Institutes
- Others
By Specimen Type
- Nasal Swab
- Nasopharyngeal (NP) Swab
- Oropharyngeal(OP) Swab
- Blood Plasma/Serum/Whole Blood
- Others
By Testing Type
- Antigen Testing
- Antibody Testing
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Forecast
Years: 2020- 2028
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of COVID Rapid Testing Market
6. Market
Synopsis: COVID Rapid Testing Market
7. COVID Rapid
Testing Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
COVID Rapid Testing Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: COVID Rapid Testing Market
7.6. Porter’s Five Force Analysis
7.7. Analysis
on Impact of Covid-19 on Global COVID Rapid Testing Market
8. Global
COVID Rapid Testing Market Analysis and Forecasts, 2020- 2028
8.1. Overview
8.1.1. Global
COVID Rapid Testing Market Revenue (US$ Mn)
8.2. Global
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales Channel
8.2.1. Direct
8.2.1.1. Definition
8.2.1.2. Market
Forecast, 2020- 2028
8.2.1.3. Compound
Annual Growth Rate (CAGR)
8.2.1.4. Regional
Bifurcation
8.2.1.4.1. North
America
8.2.1.4.1.1. Market
Forecast, 2020- 2028
8.2.1.4.2. Europe
8.2.1.4.2.1. Market
Forecast, 2020- 2028
8.2.1.4.3. Asia
Pacific
8.2.1.4.3.1. Market
Forecast, 2020- 2028
8.2.1.4.4. Middle
East and Africa
8.2.1.4.4.1. Market
Forecast, 2020- 2028
8.2.1.4.5. Latin
America
8.2.1.4.5.1. Market
Forecast, 2020- 2028
8.2.2. Indirect
8.2.2.1. Definition
8.2.2.2. Market
Forecast, 2020- 2028
8.2.2.3. Compound
Annual Growth Rate (CAGR)
8.2.2.4. Regional
Bifurcation
8.2.2.4.1. North
America
8.2.2.4.1.1. Market
Forecast, 2020- 2028
8.2.2.4.2. Europe
8.2.2.4.2.1. Market
Forecast, 2020- 2028
8.2.2.4.3. Asia
Pacific
8.2.2.4.3.1. Market
Forecast, 2020- 2028
8.2.2.4.4. Middle
East and Africa
8.2.2.4.4.1. Market
Forecast, 2020- 2028
8.2.2.4.5. Latin
America
8.2.2.4.5.1. Market
Forecast, 2020- 2028
8.3. Key
Segment for Channeling Investments
8.3.1. By Sales
Channel
9. Global
COVID Rapid Testing Market Analysis and Forecasts, 2020- 2028
9.1. Overview
9.2. Global
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
9.2.1. Hospitals
9.2.1.1. Definition
9.2.1.2. Market
Forecast, 2020- 2028
9.2.1.3. Compound
Annual Growth Rate (CAGR)
9.2.1.4. Regional
Bifurcation
9.2.1.4.1. North
America
9.2.1.4.1.1. Market
Forecast, 2020- 2028
9.2.1.4.2. Europe
9.2.1.4.2.1. Market
Forecast, 2020- 2028
9.2.1.4.3. Asia
Pacific
9.2.1.4.3.1. Market
Forecast, 2020- 2028
9.2.1.4.4. Middle
East and Africa
9.2.1.4.4.1. Market
Forecast, 2020- 2028
9.2.1.4.5. Latin
America
9.2.1.4.5.1. Market
Forecast, 2020- 2028
9.2.2. Clinics
9.2.2.1. Definition
9.2.2.2. Market
Forecast, 2020- 2028
9.2.2.3. Compound
Annual Growth Rate (CAGR)
9.2.2.4. Regional
Bifurcation
9.2.2.4.1. North
America
9.2.2.4.1.1. Market
Forecast, 2020- 2028
9.2.2.4.2. Europe
9.2.2.4.2.1. Market
Forecast, 2020- 2028
9.2.2.4.3. Asia
Pacific
9.2.2.4.3.1. Market
Forecast, 2020- 2028
9.2.2.4.4. Middle
East and Africa
9.2.2.4.4.1. Market
Forecast, 2020- 2028
9.2.2.4.5. Latin
America
9.2.2.4.5.1. Market
Forecast, 2020- 2028
9.2.3. Laboratories
9.2.3.1. Definition
9.2.3.2. Market
Forecast, 2020- 2028
9.2.3.3. Compound
Annual Growth Rate (CAGR)
9.2.3.4. Regional
Bifurcation
9.2.3.4.1. North
America
9.2.3.4.1.1. Market
Forecast, 2020- 2028
9.2.3.4.2. Europe
9.2.3.4.2.1. Market
Forecast, 2020- 2028
9.2.3.4.3. Asia
Pacific
9.2.3.4.3.1. Market
Forecast, 2020- 2028
9.2.3.4.4. Middle
East and Africa
9.2.3.4.4.1. Market
Forecast, 2020- 2028
9.2.3.4.5. Latin
America
9.2.3.4.5.1. Market
Forecast, 2020- 2028
9.2.4. Pathological
Centres
9.2.4.1. Definition
9.2.4.2. Market
Forecast, 2020- 2028
9.2.4.3. Compound
Annual Growth Rate (CAGR)
9.2.4.4. Regional
Bifurcation
9.2.4.4.1. North
America
9.2.4.4.1.1. Market
Forecast, 2020- 2028
9.2.4.4.2. Europe
9.2.4.4.2.1. Market
Forecast, 2020- 2028
9.2.4.4.3. Asia
Pacific
9.2.4.4.3.1. Market
Forecast, 2020- 2028
9.2.4.4.4. Middle
East and Africa
9.2.4.4.4.1. Market
Forecast, 2020- 2028
9.2.4.4.5. Latin
America
9.2.4.4.5.1. Market
Forecast, 2020- 2028
9.2.5. Research
Institutes
9.2.5.1. Definition
9.2.5.2. Market
Forecast, 2020- 2028
9.2.5.3. Compound
Annual Growth Rate (CAGR)
9.2.5.4. Regional
Bifurcation
9.2.5.4.1. North
America
9.2.5.4.1.1. Market
Forecast, 2020- 2028
9.2.5.4.2. Europe
9.2.5.4.2.1. Market
Forecast, 2020- 2028
9.2.5.4.3. Asia
Pacific
9.2.5.4.3.1. Market
Forecast, 2020- 2028
9.2.5.4.4. Middle
East and Africa
9.2.5.4.4.1. Market
Forecast, 2020- 2028
9.2.5.4.5. Latin
America
9.2.5.4.5.1. Market
Forecast, 2020- 2028
9.2.6. Others
9.2.6.1. Definition
9.2.6.2. Market
Forecast, 2020- 2028
9.2.6.3. Compound
Annual Growth Rate (CAGR)
9.2.6.4. Regional
Bifurcation
9.2.6.4.1. North
America
9.2.6.4.1.1. Market
Forecast, 2020- 2028
9.2.6.4.2. Europe
9.2.6.4.2.1. Market
Forecast, 2020- 2028
9.2.6.4.3. Asia
Pacific
9.2.6.4.3.1. Market
Forecast, 2020- 2028
9.2.6.4.4. Middle
East and Africa
9.2.6.4.4.1. Market
Forecast, 2020- 2028
9.2.6.4.5. Latin
America
9.2.6.4.5.1. Market
Forecast, 2020- 2028
9.3. Key
Segment for Channeling Investments
9.3.1. By
End-Users
10. Global
COVID Rapid Testing Market Analysis and Forecasts, 2020- 2028
10.1. Overview
10.2. Global
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen Type
10.2.1. Nasal
Swab
10.2.1.1. Definition
10.2.1.2. Market
Forecast, 2020- 2028
10.2.1.3. Compound
Annual Growth Rate (CAGR)
10.2.1.4. Regional
Bifurcation
10.2.1.4.1. North
America
10.2.1.4.1.1. Market
Forecast, 2020- 2028
10.2.1.4.2. Europe
10.2.1.4.2.1. Market
Forecast, 2020- 2028
10.2.1.4.3. Asia
Pacific
10.2.1.4.3.1. Market
Forecast, 2020- 2028
10.2.1.4.4. Middle
East and Africa
10.2.1.4.4.1. Market
Forecast, 2020- 2028
10.2.1.4.5. Latin
America
10.2.1.4.5.1. Market
Forecast, 2020- 2028
10.2.2. Nasopharyngeal
(NP) Swab
10.2.2.1. Definition
10.2.2.2. Market
Forecast, 2020- 2028
10.2.2.3. Compound
Annual Growth Rate (CAGR)
10.2.2.4. Regional
Bifurcation
10.2.2.4.1. North
America
10.2.2.4.1.1. Market
Forecast, 2020- 2028
10.2.2.4.2. Europe
10.2.2.4.2.1. Market
Forecast, 2020- 2028
10.2.2.4.3. Asia
Pacific
10.2.2.4.3.1. Market
Forecast, 2020- 2028
10.2.2.4.4. Middle
East and Africa
10.2.2.4.4.1. Market
Forecast, 2020- 2028
10.2.2.4.5. Latin
America
10.2.2.4.5.1. Market
Forecast, 2020- 2028
10.2.3. Oropharyngeal(OP)
Swab
10.2.3.1. Definition
10.2.3.2. Market
Forecast, 2020- 2028
10.2.3.3. Compound
Annual Growth Rate (CAGR)
10.2.3.4. Regional
Bifurcation
10.2.3.4.1. North
America
10.2.3.4.1.1. Market
Forecast, 2020- 2028
10.2.3.4.2. Europe
10.2.3.4.2.1. Market
Forecast, 2020- 2028
10.2.3.4.3. Asia
Pacific
10.2.3.4.3.1. Market
Forecast, 2020- 2028
10.2.3.4.4. Middle
East and Africa
10.2.3.4.4.1. Market
Forecast, 2020- 2028
10.2.3.4.5. Latin
America
10.2.3.4.5.1. Market
Forecast, 2020- 2028
10.2.4. Blood
Plasma/Serum/Whole Blood
10.2.4.1. Definition
10.2.4.2. Market
Forecast, 2020- 2028
10.2.4.3. Compound
Annual Growth Rate (CAGR)
10.2.4.4. Regional
Bifurcation
10.2.4.4.1. North
America
10.2.4.4.1.1. Market
Forecast, 2020- 2028
10.2.4.4.2. Europe
10.2.4.4.2.1. Market
Forecast, 2020- 2028
10.2.4.4.3. Asia
Pacific
10.2.4.4.3.1. Market
Forecast, 2020- 2028
10.2.4.4.4. Middle
East and Africa
10.2.4.4.4.1. Market
Forecast, 2020- 2028
10.2.4.4.5. Latin
America
10.2.4.4.5.1. Market
Forecast, 2020- 2028
10.2.5. Others
10.2.5.1. Definition
10.2.5.2. Market
Forecast, 2020- 2028
10.2.5.3. Compound
Annual Growth Rate (CAGR)
10.2.5.4. Regional
Bifurcation
10.2.5.4.1. North
America
10.2.5.4.1.1. Market
Forecast, 2020- 2028
10.2.5.4.2. Europe
10.2.5.4.2.1. Market
Forecast, 2020- 2028
10.2.5.4.3. Asia
Pacific
10.2.5.4.3.1. Market
Forecast, 2020- 2028
10.2.5.4.4. Middle
East and Africa
10.2.5.4.4.1. Market
Forecast, 2020- 2028
10.2.5.4.5. Latin
America
10.2.5.4.5.1. Market
Forecast, 2020- 2028
10.3. Key
Segment for Channeling Investments
10.3.1. By
Specimen Type
11. Global
COVID Rapid Testing Market Analysis and Forecasts, 2020- 2028
11.1. Overview
11.2. Global
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
11.2.1. Antigen
Testing
11.2.1.1. Definition
11.2.1.2. Market
Forecast, 2020- 2028
11.2.1.3. Compound
Annual Growth Rate (CAGR)
11.2.1.4. Regional
Bifurcation
11.2.1.4.1. North
America
11.2.1.4.1.1. Market
Forecast, 2020- 2028
11.2.1.4.2. Europe
11.2.1.4.2.1. Market
Forecast, 2020- 2028
11.2.1.4.3. Asia
Pacific
11.2.1.4.3.1. Market
Forecast, 2020- 2028
11.2.1.4.4. Middle
East and Africa
11.2.1.4.4.1. Market
Forecast, 2020- 2028
11.2.1.4.5. Latin
America
11.2.1.4.5.1. Market
Forecast, 2020- 2028
11.2.2. Antibody
Testing
11.2.2.1. Definition
11.2.2.2. Market
Forecast, 2020- 2028
11.2.2.3. Compound
Annual Growth Rate (CAGR)
11.2.2.4. Regional
Bifurcation
11.2.2.4.1. North
America
11.2.2.4.1.1. Market
Forecast, 2020- 2028
11.2.2.4.2. Europe
11.2.2.4.2.1. Market
Forecast, 2020- 2028
11.2.2.4.3. Asia
Pacific
11.2.2.4.3.1. Market
Forecast, 2020- 2028
11.2.2.4.4. Middle
East and Africa
11.2.2.4.4.1. Market
Forecast, 2020- 2028
11.2.2.4.5. Latin
America
11.2.2.4.5.1. Market
Forecast, 2020- 2028
11.3. Key
Segment for Channeling Investments
11.3.1. By
Testing Type
12. North
America COVID Rapid Testing Market Analysis and Forecasts, 2020 - 2028
12.1. Overview
12.1.1. North
America COVID Rapid Testing Market Revenue (US$ Mn)
12.2. North
America COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales
Channel
12.2.1. Direct
12.2.2. Indirect
12.3. North
America COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
12.3.1. Hospitals
12.3.2. Clinics
12.3.3. Laboratories
12.3.4. Pathological
Centres
12.3.5. Research
Institutes
12.3.6. Others
12.4. North
America COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen
Type
12.4.1. Nasal
Swab
12.4.2. Nasopharyngeal
(NP) Swab
12.4.3. Oropharyngeal(OP)
Swab
12.4.4. Blood
Plasma/Serum/Whole Blood
12.4.5. Others
12.5. North
America COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing
Type
12.5.1. Antigen
Testing
12.5.2. Antibody
Testing
12.6. North
America COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales Channel
12.6.1.1.1. Direct
12.6.1.1.2. Indirect
12.6.1.2. U.S
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
12.6.1.2.1. Hospitals
12.6.1.2.2. Clinics
12.6.1.2.3. Laboratories
12.6.1.2.4. Pathological
Centres
12.6.1.2.5. Research
Institutes
12.6.1.2.6. Others
12.6.1.3. U.S
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen Type
12.6.1.3.1. Nasal
Swab
12.6.1.3.2. Nasopharyngeal
(NP) Swab
12.6.1.3.3. Oropharyngeal(OP)
Swab
12.6.1.3.4. Blood
Plasma/Serum/Whole Blood
12.6.1.3.5. Others
12.6.1.4. U.S
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
12.6.1.4.1. Antigen
Testing
12.6.1.4.2. Antibody
Testing
12.6.2. Canada
12.6.2.1. Canada
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales Channel
12.6.2.1.1. Direct
12.6.2.1.2. Indirect
12.6.2.2. Canada
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
12.6.2.2.1. Hospitals
12.6.2.2.2. Clinics
12.6.2.2.3. Laboratories
12.6.2.2.4. Pathological
Centres
12.6.2.2.5. Research
Institutes
12.6.2.2.6. Others
12.6.2.3. Canada
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen Type
12.6.2.3.1. Nasal
Swab
12.6.2.3.2. Nasopharyngeal
(NP) Swab
12.6.2.3.3. Oropharyngeal(OP)
Swab
12.6.2.3.4. Blood
Plasma/Serum/Whole Blood
12.6.2.3.5. Others
12.6.2.4. Canada
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
12.6.2.4.1. Antigen
Testing
12.6.2.4.2. Antibody
Testing
12.6.3. Mexico
12.6.3.1. Mexico
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales Channel
12.6.3.1.1. Direct
12.6.3.1.2. Indirect
12.6.3.2. Mexico
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
12.6.3.2.1. Hospitals
12.6.3.2.2. Clinics
12.6.3.2.3. Laboratories
12.6.3.2.4. Pathological
Centres
12.6.3.2.5. Research
Institutes
12.6.3.2.6. Others
12.6.3.3. Mexico
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen Type
12.6.3.3.1. Nasal
Swab
12.6.3.3.2. Nasopharyngeal
(NP) Swab
12.6.3.3.3. Oropharyngeal(OP)
Swab
12.6.3.3.4. Blood
Plasma/Serum/Whole Blood
12.6.3.3.5. Others
12.6.3.4. Mexico
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
12.6.3.4.1. Antigen
Testing
12.6.3.4.2. Antibody
Testing
12.6.4. Rest of
North America
12.6.4.1. Rest
of North America COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
Sales Channel
12.6.4.1.1. Direct
12.6.4.1.2. Indirect
12.6.4.2. Rest
of North America COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
End-Users
12.6.4.2.1. Hospitals
12.6.4.2.2. Clinics
12.6.4.2.3. Laboratories
12.6.4.2.4. Pathological
Centres
12.6.4.2.5. Research
Institutes
12.6.4.2.6. Others
12.6.4.3. Rest
of North America COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
Specimen Type
12.6.4.3.1. Nasal
Swab
12.6.4.3.2. Nasopharyngeal
(NP) Swab
12.6.4.3.3. Oropharyngeal(OP)
Swab
12.6.4.3.4. Blood
Plasma/Serum/Whole Blood
12.6.4.3.5. Others
12.6.4.4. Rest
of North America COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
Testing Type
12.6.4.4.1. Antigen
Testing
12.6.4.4.2. Antibody
Testing
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By
Sales Channel
12.7.3. By
End-Users
12.7.4. By
Specimen Type
12.7.5. By
Testing Type
13. Europe
COVID Rapid Testing Market Analysis and Forecasts, 2020 - 2028
13.1. Overview
13.1.1. Europe
COVID Rapid Testing Market Revenue (US$ Mn)
13.2. Europe
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales Channel
13.2.1. Direct
13.2.2. Indirect
13.3. Europe
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
13.3.1. Hospitals
13.3.2. Clinics
13.3.3. Laboratories
13.3.4. Pathological
Centres
13.3.5. Research
Institutes
13.3.6. Others
13.4. Europe
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen Type
13.4.1. Nasal
Swab
13.4.2. Nasopharyngeal
(NP) Swab
13.4.3. Oropharyngeal(OP)
Swab
13.4.4. Blood
Plasma/Serum/Whole Blood
13.4.5. Others
13.5. Europe
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
13.5.1. Antigen
Testing
13.5.2. Antibody
Testing
13.6. Europe
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales Channel
13.6.1.1.1. Direct
13.6.1.1.2. Indirect
13.6.1.2. France
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
13.6.1.2.1. Hospitals
13.6.1.2.2. Clinics
13.6.1.2.3. Laboratories
13.6.1.2.4. Pathological
Centres
13.6.1.2.5. Research
Institutes
13.6.1.2.6. Others
13.6.1.3. France
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen Type
13.6.1.3.1. Nasal
Swab
13.6.1.3.2. Nasopharyngeal
(NP) Swab
13.6.1.3.3. Oropharyngeal(OP)
Swab
13.6.1.3.4. Blood
Plasma/Serum/Whole Blood
13.6.1.3.5. Others
13.6.1.4. France
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
13.6.1.4.1. Antigen
Testing
13.6.1.4.2. Antibody
Testing
13.6.2. The UK
13.6.2.1. The
UK COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales Channel
13.6.2.1.1. Direct
13.6.2.1.2. Indirect
13.6.2.2. The
UK COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
13.6.2.2.1. Hospitals
13.6.2.2.2. Clinics
13.6.2.2.3. Laboratories
13.6.2.2.4. Pathological
Centres
13.6.2.2.5. Research
Institutes
13.6.2.2.6. Others
13.6.2.3. The
UK COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen Type
13.6.2.3.1. Nasal
Swab
13.6.2.3.2. Nasopharyngeal
(NP) Swab
13.6.2.3.3. Oropharyngeal(OP)
Swab
13.6.2.3.4. Blood
Plasma/Serum/Whole Blood
13.6.2.3.5. Others
13.6.2.4. The
UK COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
13.6.2.4.1. Antigen
Testing
13.6.2.4.2. Antibody
Testing
13.6.3. Spain
13.6.3.1. Spain
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales Channel
13.6.3.1.1. Direct
13.6.3.1.2. Indirect
13.6.3.2. Spain
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
13.6.3.2.1. Hospitals
13.6.3.2.2. Clinics
13.6.3.2.3. Laboratories
13.6.3.2.4. Pathological
Centres
13.6.3.2.5. Research
Institutes
13.6.3.2.6. Others
13.6.3.3. Spain
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen Type
13.6.3.3.1. Nasal
Swab
13.6.3.3.2. Nasopharyngeal
(NP) Swab
13.6.3.3.3. Oropharyngeal(OP)
Swab
13.6.3.3.4. Blood
Plasma/Serum/Whole Blood
13.6.3.3.5. Others
13.6.3.4. Spain
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
13.6.3.4.1. Antigen
Testing
13.6.3.4.2. Antibody
Testing
13.6.4. Germany
13.6.4.1. Germany
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales Channel
13.6.4.1.1. Direct
13.6.4.1.2. Indirect
13.6.4.2. Germany
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
13.6.4.2.1. Hospitals
13.6.4.2.2. Clinics
13.6.4.2.3. Laboratories
13.6.4.2.4. Pathological
Centres
13.6.4.2.5. Research
Institutes
13.6.4.2.6. Others
13.6.4.3. Germany
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen Type
13.6.4.3.1. Nasal
Swab
13.6.4.3.2. Nasopharyngeal
(NP) Swab
13.6.4.3.3. Oropharyngeal(OP)
Swab
13.6.4.3.4. Blood
Plasma/Serum/Whole Blood
13.6.4.3.5. Others
13.6.4.4. Germany
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
13.6.4.4.1. Antigen
Testing
13.6.4.4.2. Antibody
Testing
13.6.5. Italy
13.6.5.1. Italy
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales Channel
13.6.5.1.1. Direct
13.6.5.1.2. Indirect
13.6.5.2. Italy
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
13.6.5.2.1. Hospitals
13.6.5.2.2. Clinics
13.6.5.2.3. Laboratories
13.6.5.2.4. Pathological
Centres
13.6.5.2.5. Research
Institutes
13.6.5.2.6. Others
13.6.5.3. Italy
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen Type
13.6.5.3.1. Nasal
Swab
13.6.5.3.2. Nasopharyngeal
(NP) Swab
13.6.5.3.3. Oropharyngeal(OP)
Swab
13.6.5.3.4. Blood
Plasma/Serum/Whole Blood
13.6.5.3.5. Others
13.6.5.4. Italy
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
13.6.5.4.1. Antigen
Testing
13.6.5.4.2. Antibody
Testing
13.6.6. Nordic
Countries
13.6.6.1. Nordic
Countries COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales
Channel
13.6.6.1.1. Direct
13.6.6.1.2. Indirect
13.6.6.2. Nordic
Countries COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
End-Users
13.6.6.2.1. Hospitals
13.6.6.2.2. Clinics
13.6.6.2.3. Laboratories
13.6.6.2.4. Pathological
Centres
13.6.6.2.5. Research
Institutes
13.6.6.2.6. Others
13.6.6.3. Nordic
Countries COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
Specimen Type
13.6.6.3.1. Nasal
Swab
13.6.6.3.2. Nasopharyngeal
(NP) Swab
13.6.6.3.3. Oropharyngeal(OP)
Swab
13.6.6.3.4. Blood
Plasma/Serum/Whole Blood
13.6.6.3.5. Others
13.6.6.4. Nordic
Countries COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing
Type
13.6.6.4.1. Antigen
Testing
13.6.6.4.2. Antibody
Testing
13.6.6.5. Nordic
Countries COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux
Union COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales
Channel
13.6.7.1.1. Direct
13.6.7.1.2. Indirect
13.6.7.2. Benelux
Union COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
13.6.7.2.1. Hospitals
13.6.7.2.2. Clinics
13.6.7.2.3. Laboratories
13.6.7.2.4. Pathological
Centres
13.6.7.2.5. Research
Institutes
13.6.7.2.6. Others
13.6.7.3. Benelux
Union COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen
Type
13.6.7.3.1. Nasal
Swab
13.6.7.3.2. Nasopharyngeal
(NP) Swab
13.6.7.3.3. Oropharyngeal(OP)
Swab
13.6.7.3.4. Blood
Plasma/Serum/Whole Blood
13.6.7.3.5. Others
13.6.7.4. Benelux
Union COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing
Type
13.6.7.4.1. Antigen
Testing
13.6.7.4.2. Antibody
Testing
13.6.7.5. Benelux
Union COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The
Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest
of Europe COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales
Channel
13.6.8.1.1. Direct
13.6.8.1.2. Indirect
13.6.8.2. Rest
of Europe COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
End-Users
13.6.8.2.1. Hospitals
13.6.8.2.2. Clinics
13.6.8.2.3. Laboratories
13.6.8.2.4. Pathological
Centres
13.6.8.2.5. Research
Institutes
13.6.8.2.6. Others
13.6.8.3. Rest
of Europe COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
Specimen Type
13.6.8.3.1. Nasal
Swab
13.6.8.3.2. Nasopharyngeal
(NP) Swab
13.6.8.3.3. Oropharyngeal(OP)
Swab
13.6.8.3.4. Blood
Plasma/Serum/Whole Blood
13.6.8.3.5. Others
13.6.8.4. Rest
of Europe COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing
Type
13.6.8.4.1. Antigen
Testing
13.6.8.4.2. Antibody
Testing
13.7. Key
Segment for Channeling Investments
13.7.1. By
Country
13.7.2. By
Sales Channel
13.7.3. By
End-Users
13.7.4. By
Specimen Type
13.7.5. By
Testing Type
14. Asia
Pacific COVID Rapid Testing Market Analysis and Forecasts, 2020 - 2028
14.1. Overview
14.1.1. Asia
Pacific COVID Rapid Testing Market Revenue (US$ Mn)
14.2. Asia
Pacific COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales
Channel
14.2.1. Direct
14.2.2. Indirect
14.3. Asia
Pacific COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
14.3.1. Hospitals
14.3.2. Clinics
14.3.3. Laboratories
14.3.4. Pathological
Centres
14.3.5. Research
Institutes
14.3.6. Others
14.4. Asia
Pacific COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen
Type
14.4.1. Nasal
Swab
14.4.2. Nasopharyngeal
(NP) Swab
14.4.3. Oropharyngeal(OP)
Swab
14.4.4. Blood
Plasma/Serum/Whole Blood
14.4.5. Others
14.5. Asia
Pacific COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing
Type
14.5.1. Antigen
Testing
14.5.2. Antibody
Testing
14.6. Asia
Pacific COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1. China
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales Channel
14.6.1.1.1. Direct
14.6.1.1.2. Indirect
14.6.1.2. China
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
14.6.1.2.1. Hospitals
14.6.1.2.2. Clinics
14.6.1.2.3. Laboratories
14.6.1.2.4. Pathological
Centres
14.6.1.2.5. Research
Institutes
14.6.1.2.6. Others
14.6.1.3. China
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen Type
14.6.1.3.1. Nasal
Swab
14.6.1.3.2. Nasopharyngeal
(NP) Swab
14.6.1.3.3. Oropharyngeal(OP)
Swab
14.6.1.3.4. Blood
Plasma/Serum/Whole Blood
14.6.1.3.5. Others
14.6.1.4. China
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
14.6.1.4.1. Antigen
Testing
14.6.1.4.2. Antibody
Testing
14.6.2. Japan
14.6.2.1. Japan
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales Channel
14.6.2.1.1. Direct
14.6.2.1.2. Indirect
14.6.2.2. Japan
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
14.6.2.2.1. Hospitals
14.6.2.2.2. Clinics
14.6.2.2.3. Laboratories
14.6.2.2.4. Pathological
Centres
14.6.2.2.5. Research
Institutes
14.6.2.2.6. Others
14.6.2.3. Japan
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen Type
14.6.2.3.1. Nasal
Swab
14.6.2.3.2. Nasopharyngeal
(NP) Swab
14.6.2.3.3. Oropharyngeal(OP)
Swab
14.6.2.3.4. Blood
Plasma/Serum/Whole Blood
14.6.2.3.5. Others
14.6.2.4. Japan
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
14.6.2.4.1. Antigen
Testing
14.6.2.4.2. Antibody
Testing
14.6.3. India
14.6.3.1. India
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales Channel
14.6.3.1.1. Direct
14.6.3.1.2. Indirect
14.6.3.2. India
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
14.6.3.2.1. Hospitals
14.6.3.2.2. Clinics
14.6.3.2.3. Laboratories
14.6.3.2.4. Pathological
Centres
14.6.3.2.5. Research
Institutes
14.6.3.2.6. Others
14.6.3.3. India
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen Type
14.6.3.3.1. Nasal
Swab
14.6.3.3.2. Nasopharyngeal
(NP) Swab
14.6.3.3.3. Oropharyngeal(OP)
Swab
14.6.3.3.4. Blood
Plasma/Serum/Whole Blood
14.6.3.3.5. Others
14.6.3.4. India
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
14.6.3.4.1. Antigen
Testing
14.6.3.4.2. Antibody
Testing
14.6.4. New
Zealand
14.6.4.1. New
Zealand COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales
Channel
14.6.4.1.1. Direct
14.6.4.1.2. Indirect
14.6.4.2. New
Zealand COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
14.6.4.2.1. Hospitals
14.6.4.2.2. Clinics
14.6.4.2.3. Laboratories
14.6.4.2.4. Pathological
Centres
14.6.4.2.5. Research
Institutes
14.6.4.2.6. Others
14.6.4.3. New
Zealand COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen
Type
14.6.4.3.1. Nasal
Swab
14.6.4.3.2. Nasopharyngeal
(NP) Swab
14.6.4.3.3. Oropharyngeal(OP)
Swab
14.6.4.3.4. Blood
Plasma/Serum/Whole Blood
14.6.4.3.5. Others
14.6.4.4. New
Zealand COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing
Type
14.6.4.4.1. Antigen
Testing
14.6.4.4.2. Antibody
Testing
14.6.5. Australia
14.6.5.1. Australia
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales Channel
14.6.5.1.1. Direct
14.6.5.1.2. Indirect
14.6.5.2. Australia
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
14.6.5.2.1. Hospitals
14.6.5.2.2. Clinics
14.6.5.2.3. Laboratories
14.6.5.2.4. Pathological
Centres
14.6.5.2.5. Research
Institutes
14.6.5.2.6. Others
14.6.5.3. Australia
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen Type
14.6.5.3.1. Nasal
Swab
14.6.5.3.2. Nasopharyngeal
(NP) Swab
14.6.5.3.3. Oropharyngeal(OP)
Swab
14.6.5.3.4. Blood
Plasma/Serum/Whole Blood
14.6.5.3.5. Others
14.6.5.4. Australia
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
14.6.5.4.1. Antigen
Testing
14.6.5.4.2. Antibody
Testing
14.6.6. South
Korea
14.6.6.1. South
Korea COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales
Channel
14.6.6.1.1. Direct
14.6.6.1.2. Indirect
14.6.6.2. South
Korea COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
14.6.6.2.1. Hospitals
14.6.6.2.2. Clinics
14.6.6.2.3. Laboratories
14.6.6.2.4. Pathological
Centres
14.6.6.2.5. Research
Institutes
14.6.6.2.6. Others
14.6.6.3. South
Korea COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen
Type
14.6.6.3.1. Nasal
Swab
14.6.6.3.2. Nasopharyngeal
(NP) Swab
14.6.6.3.3. Oropharyngeal(OP)
Swab
14.6.6.3.4. Blood
Plasma/Serum/Whole Blood
14.6.6.3.5. Others
14.6.6.4. South
Korea COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing
Type
14.6.6.4.1. Antigen
Testing
14.6.6.4.2. Antibody
Testing
14.6.7. Southeast
Asia
14.6.7.1. Southeast
Asia COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales
Channel
14.6.7.1.1. Direct
14.6.7.1.2. Indirect
14.6.7.2. Southeast
Asia COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
14.6.7.2.1. Hospitals
14.6.7.2.2. Clinics
14.6.7.2.3. Laboratories
14.6.7.2.4. Pathological
Centres
14.6.7.2.5. Research
Institutes
14.6.7.2.6. Others
14.6.7.3. Southeast
Asia COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen
Type
14.6.7.3.1. Nasal
Swab
14.6.7.3.2. Nasopharyngeal
(NP) Swab
14.6.7.3.3. Oropharyngeal(OP)
Swab
14.6.7.3.4. Blood
Plasma/Serum/Whole Blood
14.6.7.3.5. Others
14.6.7.4. Southeast
Asia COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
14.6.7.4.1. Antigen
Testing
14.6.7.4.2. Antibody
Testing
14.6.7.5. Southeast
Asia COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest
of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest
of Asia Pacific COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
Sales Channel
14.6.8.1.1. Direct
14.6.8.1.2. Indirect
14.6.8.2. Rest
of Asia Pacific COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
End-Users
14.6.8.2.1. Hospitals
14.6.8.2.2. Clinics
14.6.8.2.3. Laboratories
14.6.8.2.4. Pathological
Centres
14.6.8.2.5. Research
Institutes
14.6.8.2.6. Others
14.6.8.3. Rest
of Asia Pacific COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
Specimen Type
14.6.8.3.1. Nasal
Swab
14.6.8.3.2. Nasopharyngeal
(NP) Swab
14.6.8.3.3. Oropharyngeal(OP)
Swab
14.6.8.3.4. Blood
Plasma/Serum/Whole Blood
14.6.8.3.5. Others
14.6.8.4. Rest
of Asia Pacific COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
Testing Type
14.6.8.4.1. Antigen
Testing
14.6.8.4.2. Antibody
Testing
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By
Sales Channel
14.7.3. By
End-Users
14.7.4. By
Specimen Type
14.7.5. By
Testing Type
15. Middle
East and Africa COVID Rapid Testing Market Analysis and Forecasts, 2020 - 2028
15.1. Overview
15.1.1. Middle East
and Africa COVID Rapid Testing Market Revenue (US$ Mn)
15.2. Middle
East and Africa COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
Sales Channel
15.2.1. Direct
15.2.2. Indirect
15.3. Middle
East and Africa COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
End-Users
15.3.1. Hospitals
15.3.2. Clinics
15.3.3. Laboratories
15.3.4. Pathological
Centres
15.3.5. Research
Institutes
15.3.6. Others
15.4. Middle
East and Africa COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
Specimen Type
15.4.1. Nasal
Swab
15.4.2. Nasopharyngeal
(NP) Swab
15.4.3. Oropharyngeal(OP)
Swab
15.4.4. Blood
Plasma/Serum/Whole Blood
15.4.5. Others
15.5. Middle
East and Africa COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
Testing Type
15.5.1. Antigen
Testing
15.5.2. Antibody
Testing
15.6. Middle
East and Africa COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi
Arabia COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales
Channel
15.6.1.1.1. Direct
15.6.1.1.2. Indirect
15.6.1.2. Saudi
Arabia COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
15.6.1.2.1. Hospitals
15.6.1.2.2. Clinics
15.6.1.2.3. Laboratories
15.6.1.2.4. Pathological
Centres
15.6.1.2.5. Research
Institutes
15.6.1.2.6. Others
15.6.1.3. Saudi
Arabia COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen
Type
15.6.1.3.1. Nasal
Swab
15.6.1.3.2. Nasopharyngeal
(NP) Swab
15.6.1.3.3. Oropharyngeal(OP)
Swab
15.6.1.3.4. Blood
Plasma/Serum/Whole Blood
15.6.1.3.5. Others
15.6.1.4. Saudi
Arabia COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing
Type
15.6.1.4.1. Antigen
Testing
15.6.1.4.2. Antibody
Testing
15.6.2. UAE
15.6.2.1. UAE
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales Channel
15.6.2.1.1. Direct
15.6.2.1.2. Indirect
15.6.2.2. UAE
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
15.6.2.2.1. Hospitals
15.6.2.2.2. Clinics
15.6.2.2.3. Laboratories
15.6.2.2.4. Pathological
Centres
15.6.2.2.5. Research
Institutes
15.6.2.2.6. Others
15.6.2.3. UAE
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen Type
15.6.2.3.1. Nasal
Swab
15.6.2.3.2. Nasopharyngeal
(NP) Swab
15.6.2.3.3. Oropharyngeal(OP)
Swab
15.6.2.3.4. Blood
Plasma/Serum/Whole Blood
15.6.2.3.5. Others
15.6.2.4. UAE
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
15.6.2.4.1. Antigen
Testing
15.6.2.4.2. Antibody
Testing
15.6.3. Egypt
15.6.3.1. Egypt
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales Channel
15.6.3.1.1. Direct
15.6.3.1.2. Indirect
15.6.3.2. Egypt
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
15.6.3.2.1. Hospitals
15.6.3.2.2. Clinics
15.6.3.2.3. Laboratories
15.6.3.2.4. Pathological
Centres
15.6.3.2.5. Research
Institutes
15.6.3.2.6. Others
15.6.3.3. Egypt
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen Type
15.6.3.3.1. Nasal
Swab
15.6.3.3.2. Nasopharyngeal
(NP) Swab
15.6.3.3.3. Oropharyngeal(OP)
Swab
15.6.3.3.4. Blood
Plasma/Serum/Whole Blood
15.6.3.3.5. Others
15.6.3.4. Egypt
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
15.6.3.4.1. Antigen
Testing
15.6.3.4.2. Antibody
Testing
15.6.4. Kuwait
15.6.4.1. Kuwait
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales Channel
15.6.4.1.1. Direct
15.6.4.1.2. Indirect
15.6.4.2. Kuwait
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
15.6.4.2.1. Hospitals
15.6.4.2.2. Clinics
15.6.4.2.3. Laboratories
15.6.4.2.4. Pathological
Centres
15.6.4.2.5. Research
Institutes
15.6.4.2.6. Others
15.6.4.3. Kuwait
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen Type
15.6.4.3.1. Nasal
Swab
15.6.4.3.2. Nasopharyngeal
(NP) Swab
15.6.4.3.3. Oropharyngeal(OP)
Swab
15.6.4.3.4. Blood
Plasma/Serum/Whole Blood
15.6.4.3.5. Others
15.6.4.4. Kuwait
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
15.6.4.4.1. Antigen
Testing
15.6.4.4.2. Antibody
Testing
15.6.5. South
Africa
15.6.5.1. South
Africa COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales
Channel
15.6.5.1.1. Direct
15.6.5.1.2. Indirect
15.6.5.2. South
Africa COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
15.6.5.2.1. Hospitals
15.6.5.2.2. Clinics
15.6.5.2.3. Laboratories
15.6.5.2.4. Pathological
Centres
15.6.5.2.5. Research
Institutes
15.6.5.2.6. Others
15.6.5.3. South
Africa COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen
Type
15.6.5.3.1. Nasal
Swab
15.6.5.3.2. Nasopharyngeal
(NP) Swab
15.6.5.3.3. Oropharyngeal(OP)
Swab
15.6.5.3.4. Blood
Plasma/Serum/Whole Blood
15.6.5.3.5. Others
15.6.5.4. South
Africa COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing
Type
15.6.5.4.1. Antigen
Testing
15.6.5.4.2. Antibody
Testing
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest
of Middle East & Africa COVID Rapid Testing Market Revenue (US$ Mn) and
Forecasts, By Sales Channel
15.6.6.1.1. Direct
15.6.6.1.2. Indirect
15.6.6.2. Rest
of Middle East & Africa COVID Rapid Testing Market Revenue (US$ Mn) and
Forecasts, By End-Users
15.6.6.2.1. Hospitals
15.6.6.2.2. Clinics
15.6.6.2.3. Laboratories
15.6.6.2.4. Pathological
Centres
15.6.6.2.5. Research
Institutes
15.6.6.2.6. Others
15.6.6.3. Rest
of Middle East & Africa COVID Rapid Testing Market Revenue (US$ Mn) and
Forecasts, By Specimen Type
15.6.6.3.1. Nasal
Swab
15.6.6.3.2. Nasopharyngeal
(NP) Swab
15.6.6.3.3. Oropharyngeal(OP)
Swab
15.6.6.3.4. Blood
Plasma/Serum/Whole Blood
15.6.6.3.5. Others
15.6.6.4. Rest
of Middle East & Africa COVID Rapid Testing Market Revenue (US$ Mn) and
Forecasts, By Testing Type
15.6.6.4.1. Antigen
Testing
15.6.6.4.2. Antibody
Testing
15.7. Key
Segment for Channeling Investments
15.7.1. By Country
15.7.2. By
Sales Channel
15.7.3. By
End-Users
15.7.4. By
Specimen Type
15.7.5. By
Testing Type
16. Latin
America COVID Rapid Testing Market Analysis and Forecasts, 2020 - 2028
16.1. Overview
16.1.1. Latin
America COVID Rapid Testing Market Revenue (US$ Mn)
16.2. Latin
America COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales
Channel
16.2.1. Direct
16.2.2. Indirect
16.3. Latin
America COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
16.3.1. Hospitals
16.3.2. Clinics
16.3.3. Laboratories
16.3.4. Pathological
Centres
16.3.5. Research
Institutes
16.3.6. Others
16.4. Latin
America COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen
Type
16.4.1. Nasal
Swab
16.4.2. Nasopharyngeal
(NP) Swab
16.4.3. Oropharyngeal(OP)
Swab
16.4.4. Blood
Plasma/Serum/Whole Blood
16.4.5. Others
16.5. Latin
America COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing
Type
16.5.1. Antigen
Testing
16.5.2. Antibody
Testing
16.6. Latin
America COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales Channel
16.6.1.1.1. Direct
16.6.1.1.2. Indirect
16.6.1.2. Brazil
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
16.6.1.2.1. Hospitals
16.6.1.2.2. Clinics
16.6.1.2.3. Laboratories
16.6.1.2.4. Pathological
Centres
16.6.1.2.5. Research
Institutes
16.6.1.2.6. Others
16.6.1.3. Brazil
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen Type
16.6.1.3.1. Nasal
Swab
16.6.1.3.2. Nasopharyngeal
(NP) Swab
16.6.1.3.3. Oropharyngeal(OP)
Swab
16.6.1.3.4. Blood
Plasma/Serum/Whole Blood
16.6.1.3.5. Others
16.6.1.4. Brazil
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
16.6.1.4.1. Antigen
Testing
16.6.1.4.2. Antibody
Testing
16.6.2. Argentina
16.6.2.1. Argentina
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Sales Channel
16.6.2.1.1. Direct
16.6.2.1.2. Indirect
16.6.2.2. Argentina
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By End-Users
16.6.2.2.1. Hospitals
16.6.2.2.2. Clinics
16.6.2.2.3. Laboratories
16.6.2.2.4. Pathological
Centres
16.6.2.2.5. Research
Institutes
16.6.2.2.6. Others
16.6.2.3. Argentina
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Specimen Type
16.6.2.3.1. Nasal
Swab
16.6.2.3.2. Nasopharyngeal
(NP) Swab
16.6.2.3.3. Oropharyngeal(OP)
Swab
16.6.2.3.4. Blood
Plasma/Serum/Whole Blood
16.6.2.3.5. Others
16.6.2.4. Argentina
COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By Testing Type
16.6.2.4.1. Antigen
Testing
16.6.2.4.2. Antibody
Testing
16.6.3. Rest of
Latin America
16.6.3.1. Rest
of Latin America COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
Sales Channel
16.6.3.1.1. Direct
16.6.3.1.2. Indirect
16.6.3.2. Rest
of Latin America COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
End-Users
16.6.3.2.1. Hospitals
16.6.3.2.2. Clinics
16.6.3.2.3. Laboratories
16.6.3.2.4. Pathological
Centres
16.6.3.2.5. Research
Institutes
16.6.3.2.6. Others
16.6.3.3. Rest
of Latin America COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
Specimen Type
16.6.3.3.1. Nasal
Swab
16.6.3.3.2. Nasopharyngeal
(NP) Swab
16.6.3.3.3. Oropharyngeal(OP)
Swab
16.6.3.3.4. Blood
Plasma/Serum/Whole Blood
16.6.3.3.5. Others
16.6.3.4. Rest
of Latin America COVID Rapid Testing Market Revenue (US$ Mn) and Forecasts, By
Testing Type
16.6.3.4.1. Antigen
Testing
16.6.3.4.2. Antibody
Testing
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By
Sales Channel
16.7.3. By
End-Users
16.7.4. By
Specimen Type
16.7.5. By
Testing Type
17. Competitive
Benchmarking
17.1. Market
Share Analysis, 2019
17.2. Global
Presence and Growth Strategies
17.2.1. Mergers
and Acquisitions
17.2.2. Product
Launches
17.2.3. Investments
Trends
17.2.4. R&D
Initiatives
18. Player
Profiles
18.1. Abbot
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key
Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business
Strategies
18.2. Beijing
Tigsun Diagnostics Co,.Ltd
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key
Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business
Strategies
18.3. BGI
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT
Analysis
18.3.7. Business
Strategies
18.4. Biolidics
Limited
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business
Strategies
18.5. BioMaxima
SA
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key Developments
18.5.5. Financial
Analysis
18.5.6. SWOT
Analysis
18.5.7. Business
Strategies
18.6. BIOMEDOMICS
INC
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business
Strategies
18.7. bioMérieux
SA
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key
Developments
18.7.5. Financial
Analysis
18.7.6. SWOT
Analysis
18.7.7. Business
Strategies
18.8. Bio-Rad
Laboratories, Inc
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key
Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business
Strategies
18.9. Cellex
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key
Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business
Strategies
18.10. Cepheid
18.10.1. Company
Details
18.10.2. Company
Overview
18.10.3. Product
Offerings
18.10.4. Key
Developments
18.10.5. Financial
Analysis
18.10.6. SWOT
Analysis
18.10.7. Business
Strategies
18.11. Co-Diagnostics,
Inc.
18.11.1. Company
Details
18.11.2. Company
Overview
18.11.3. Product
Offerings
18.11.4. Key
Developments
18.11.5. Financial
Analysis
18.11.6. SWOT
Analysis
18.11.7. Business
Strategies
18.12. CTK
Biotech, Inc.
18.12.1. Company
Details
18.12.2. Company
Overview
18.12.3. Product
Offerings
18.12.4. Key
Developments
18.12.5. Financial
Analysis
18.12.6. SWOT
Analysis
18.12.7. Business
Strategies
18.13. F.
Hoffmann-La Roche Ltd
18.13.1. Company
Details
18.13.2. Company
Overview
18.13.3. Product
Offerings
18.13.4. Key
Developments
18.13.5. Financial
Analysis
18.13.6. SWOT
Analysis
18.13.7. Business
Strategies
18.14. GenMark
Diagnostics, Inc
18.14.1. Company
Details
18.14.2. Company
Overview
18.14.3. Product
Offerings
18.14.4. Key
Developments
18.14.5. Financial
Analysis
18.14.6. SWOT
Analysis
18.14.7. Business
Strategies
18.15. GeteinBiotech,Inc
18.15.1. Company
Details
18.15.2. Company
Overview
18.15.3. Product
Offerings
18.15.4. Key
Developments
18.15.5. Financial
Analysis
18.15.6. SWOT
Analysis
18.15.7. Business
Strategies
18.16. Laboratory
Corporation of America Holdings. (Pixel)
18.16.1. Company
Details
18.16.2. Company
Overview
18.16.3. Product
Offerings
18.16.4. Key
Developments
18.16.5. Financial
Analysis
18.16.6. SWOT
Analysis
18.16.7. Business
Strategies
18.17. Megna
Health
18.17.1. Company
Details
18.17.2. Company
Overview
18.17.3. Product
Offerings
18.17.4. Key
Developments
18.17.5. Financial
Analysis
18.17.6. SWOT
Analysis
18.17.7. Business
Strategies
18.18. Meridian
Life Science, Inc.
18.18.1. Company
Details
18.18.2. Company
Overview
18.18.3. Product
Offerings
18.18.4. Key
Developments
18.18.5. Financial
Analysis
18.18.6. SWOT
Analysis
18.18.7. Business
Strategies
18.19. Mylab
Discovery Solutions Pvt. Ltd.
18.19.1. Company
Details
18.19.2. Company
Overview
18.19.3. Product
Offerings
18.19.4. Key
Developments
18.19.5. Financial
Analysis
18.19.6. SWOT
Analysis
18.19.7. Business
Strategies
18.20. QIAGEN
18.20.1. Company
Details
18.20.2. Company
Overview
18.20.3. Product
Offerings
18.20.4. Key
Developments
18.20.5. Financial
Analysis
18.20.6. SWOT
Analysis
18.20.7. Business
Strategies
18.21. Quidel
Corporation
18.21.1. Company
Details
18.21.2. Company
Overview
18.21.3. Product
Offerings
18.21.4. Key
Developments
18.21.5. Financial
Analysis
18.21.6. SWOT
Analysis
18.21.7. Business
Strategies
18.22. Randox
Laboratories Ltd.
18.22.1. Company
Details
18.22.2. Company
Overview
18.22.3. Product
Offerings
18.22.4. Key
Developments
18.22.5. Financial
Analysis
18.22.6. SWOT
Analysis
18.22.7. Business
Strategies
18.23. RayBiotech,
Inc.
18.23.1. Company
Details
18.23.2. Company
Overview
18.23.3. Product
Offerings
18.23.4. Key
Developments
18.23.5. Financial
Analysis
18.23.6. SWOT
Analysis
18.23.7. Business
Strategies
18.24. SD
Biosensor, INC.
18.24.1. Company
Details
18.24.2. Company
Overview
18.24.3. Product
Offerings
18.24.4. Key
Developments
18.24.5. Financial
Analysis
18.24.6. SWOT
Analysis
18.24.7. Business
Strategies
18.25. Seegene
Inc.
18.25.1. Company
Details
18.25.2. Company
Overview
18.25.3. Product
Offerings
18.25.4. Key
Developments
18.25.5. Financial
Analysis
18.25.6. SWOT
Analysis
18.25.7. Business
Strategies
18.26. Thermo
Fisher Scientific Inc.
18.26.1. Company
Details
18.26.2. Company
Overview
18.26.3. Product
Offerings
18.26.4. Key
Developments
18.26.5. Financial
Analysis
18.26.6. SWOT
Analysis
18.26.7. Business
Strategies
18.27. Ubio
Biotechnology Systems Pvt Ltd
18.27.1. Company
Details
18.27.2. Company
Overview
18.27.3. Product
Offerings
18.27.4. Key
Developments
18.27.5. Financial
Analysis
18.27.6. SWOT
Analysis
18.27.7. Business
Strategies
18.28. Other
Industry Participants
19. Key
Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.